Nasdaq · Healthcare
GRAIL, Inc. (GRAL)
As-reported financials and recent SEC filings for GRAIL, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$147.2M
Net income
$-408.4M
Net margin
—
Diluted EPS
$-11.11
ROE
-15.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2025 | FY2024 |
|---|---|---|---|---|
| Revenue | $147.2M | $125.6M | $93.1M | $55.5M |
| Gross profit | — | — | — | — |
| Operating income | $-562.2M | $-2.19B | $-1.52B | $-5.44B |
| Net income | $-408.4M | $-2.03B | $-1.47B | $-5.40B |
| Diluted EPS | $-11.11 | $-63.54 | $-47.21 | $-173.89 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-22
View on EDGAR →42026-06-05
View on EDGAR →42026-06-03
View on EDGAR →1442026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on GRAL
Search GRAIL, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.